Arizona State Retirement System purchased a new position in shares of Heska Corporation (NASDAQ:HSKA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,360 shares of the medical research company’s stock, valued at approximately $343,000.

Several other institutional investors have also bought and sold shares of the business. OppenheimerFunds Inc. bought a new position in shares of Heska Corporation in the 1st quarter worth $451,000. Bank of New York Mellon Corp lifted its holdings in shares of Heska Corporation by 29.6% in the 1st quarter. Bank of New York Mellon Corp now owns 202,552 shares of the medical research company’s stock worth $21,264,000 after purchasing an additional 46,231 shares in the last quarter. American International Group Inc. lifted its holdings in shares of Heska Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 3,754 shares of the medical research company’s stock worth $394,000 after purchasing an additional 248 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Heska Corporation by 199.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,484 shares of the medical research company’s stock worth $155,000 after purchasing an additional 988 shares in the last quarter. Finally, Globeflex Capital L P lifted its holdings in shares of Heska Corporation by 22.3% in the 1st quarter. Globeflex Capital L P now owns 27,451 shares of the medical research company’s stock worth $2,882,000 after purchasing an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 81.44% of the company’s stock.

In other Heska Corporation news, CFO John Mcmahon sold 2,608 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the sale, the chief financial officer now directly owns 193 shares of the company’s stock, valued at $19,525.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nancy Wisnewski sold 825 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the sale, the executive vice president now directly owns 38,114 shares in the company, valued at $3,895,631.94. The disclosure for this sale can be found here. Insiders own 14.70% of the company’s stock.

Heska Corporation (NASDAQ HSKA) opened at 99.48 on Monday. The company has a market capitalization of $718.84 million, a PE ratio of 50.70 and a beta of 0.91. Heska Corporation has a one year low of $46.51 and a one year high of $115.00. The company has a 50 day moving average price of $100.24 and a 200-day moving average price of $98.24.

Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same period in the previous year, the company posted $0.35 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. Analysts expect that Heska Corporation will post $2.04 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the company. B. Riley reiterated a “neutral” rating and issued a $96.50 target price on shares of Heska Corporation in a report on Thursday, August 3rd. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Benchmark Co. reiterated a “buy” rating and issued a $120.00 target price (up from $106.00) on shares of Heska Corporation in a report on Wednesday, August 9th. Aegis increased their target price on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Friday, August 4th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $105.20.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/11/arizona-state-retirement-system-purchases-new-holdings-in-heska-corporation-hska.html.

About Heska Corporation

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Institutional Ownership by Quarter for Heska Corporation (NASDAQ:HSKA)

Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.